2-amino-3-({9-[(3β,8ξ,9ξ,14ξ,17ξ,20ξ)-cholest-5-en-3-yloxy]nonyl}oxy)-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2-amino-3-({9-[(3β,8ξ,9ξ,14ξ,17ξ,20ξ)-cholest-5-en-3-yloxy]nonyl}oxy)-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol
• 英文别名: 2-amino-3-({9-[(3beta,8xi,9xi,14xi,17xi,20xi)-cholest-5en-3-yloxy]nonyl}oxy)-2-{[(9Z, 12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol；2-amino-2-[9-[[(3S,10R,13R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]nonoxymethyl]-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-1-ol
• 化学式: C₅₈H₁₀₅NO₄
• 分子量: 880.476
• InChiKey: AQEWTCJFZAPATD-YKTHCCPOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  17.3
• 重原子数：
  63
• 可旋转键数：
  36
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  73.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-amino-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propane-1,3-diol 、 9-[(3β,8ξ,9ξ,14ξ,17ξ,20ξ)-cholest-5-en-3-yloxy]nonyl methanesulfonate 在 sodium hydride 作用下， 以 甲苯 为溶剂， 反应 24.5h， 以14%的产率得到2-amino-3-({9-[(3β,8ξ,9ξ,14ξ,17ξ,20ξ)-cholest-5-en-3-yloxy]nonyl}oxy)-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol
  参考文献：
  名称：

  [EN] NOVEL CATIONIC LIPIDS WITH VARIOUS HEAD GROUPS FOR OLIGONUCLEOTIDE DELIVERY
  [FR] NOUVEAUX LIPIDES CATIONIQUES AVEC DIFFÉRENTS GROUPES DE TÊTE POUR DÉLIVRANCE D'OLIGONUCLÉOTIDE

  摘要：

  公开号：

  WO2011022460A8

文献信息

• NOVEL CATATONIC LIPIDS WITH VARIOUS HEAD GROUPS FOR OLIGONUCLEOTIDE DELIVERY
  申请人：SIRNA THERAPEUTICS. INC.

  公开号：US20160113874A1

  公开（公告）日：2016-04-28

  The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with siRNA, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo.

  本发明提供了一种新型阳离子脂质，可以与其他脂质成分（如胆固醇和PEG脂质）结合使用，形成含有siRNA的脂质纳米粒子，以促进细胞摄取和内体逃逸，并在体外和体内靶向mRNA进行靶向RNA干扰。
• INFLUENZA HEMAGGLUTININ PROTEIN VACCINES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3939604A2

  公开（公告）日：2022-01-19

  The disclosure relates to influenza virus hemagglutinin protein and DNA vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

  本公开涉及流感病毒血凝素蛋白和 DNA 疫苗，以及使用疫苗和包含疫苗的组合物的方法。
• NOVEL CATIONIC LIPIDS WITH VARIOUS HEAD GROUPS FOR OLIGONUCLEOTIDE DELIVERY
  申请人：Cameron Mark

  公开号：US20120149894A1

  公开（公告）日：2012-06-14

  The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with siRNA, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo.
• LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS
  申请人：Gindy Marian

  公开号：US20160361411A1

  公开（公告）日：2016-12-15

  The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.
• STABILIZED RSV F PROTEINS AND USES THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210300971A1

  公开（公告）日：2021-09-30

  The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.